Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib

RYU SASAKI, MASANORI FUKUSHIMA, MASAFUMI HARAGUCHI, SATOSHI MIUMA, HISAMITSU MIYAAKI, MASAAKI HIDAKA, SUSUMU EGUCHI, SATOSHI MATSUO, TOSHIHISA MATSUZAKI, SATSUKI HASHIMOTO, KAZUO OHBA, YUKI KUGIYAMA, HIROSHI YATSUHASHI, HIDETAKA SHIBATA, YASUHIDE MOTOYOSHI, MASAYA SHIGENO, SHINICHI IWATSU, YUJI KATO, NOBORU KINOSHITA and KAZUHIKO NAKAO
Anticancer Research April 2021, 41 (4) 2025-2032; DOI: https://doi.org/10.21873/anticanres.14970
RYU SASAKI
1Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: r.sasaki@nagasaki-u.ac.jp
MASANORI FUKUSHIMA
1Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAFUMI HARAGUCHI
1Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATOSHI MIUMA
1Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HISAMITSU MIYAAKI
1Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAAKI HIDAKA
2Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUSUMU EGUCHI
2Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATOSHI MATSUO
3Gastroenterology and Hepatology, Sasebo City General Hospital, Sasebo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIHISA MATSUZAKI
3Gastroenterology and Hepatology, Sasebo City General Hospital, Sasebo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATSUKI HASHIMOTO
4Gastroenterology and Hepatology, Japan Community Health Care Organization, Isahaya, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUO OHBA
4Gastroenterology and Hepatology, Japan Community Health Care Organization, Isahaya, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKI KUGIYAMA
5Clinical Research Center, National Hospital Organization, Omura, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI YATSUHASHI
5Clinical Research Center, National Hospital Organization, Omura, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDETAKA SHIBATA
6Gastroenterology and Hepatology, Shibata Chokodo Hospital, Shimabara, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUHIDE MOTOYOSHI
7Gastroenterology and Hepatology, Nagasaki Harbor Medical Center, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAYA SHIGENO
8Gastroenterology and Hepatology, Japanese Red Cross, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINICHI IWATSU
9Gastroenterology and Hepatology, Oita Prefectural Hospital, Oita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUJI KATO
9Gastroenterology and Hepatology, Oita Prefectural Hospital, Oita, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBORU KINOSHITA
10Gastroenterology and Hepatology, Sasebo Chuo Hospital, Sasebo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUHIKO NAKAO
1Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The age of patients with advanced hepatocellular carcinoma (HCC) eligible for molecular-targeted drug treatment is increasing. We assessed liver function after lenvatinib administration according to age in patients with advanced HCC. Patients and Methods: In this retrospective, multicenter, observational study, we reviewed the records of patients with HCC who received lenvatinib treatment (March 2018-March 2020). Liver function was measured using the Albumin-Bilirubin Index (ALBI). Results: Of 119 patients, with a median age of 72.0 years, median overall survival was 15.3 months. Overall survival was significantly better in the group which maintained liver function (p=0.02). Older age (≥72 years) was associated with liver-function deterioration within 8 weeks (odds ratio=2.47, 95% confidence interval=1.06-5.75, p=0.035). The ALBI score was significantly higher in the older group at 4 and 8 weeks after lenvatinib administration. Conclusion: Lenvatinib administration was more likely to adversely affect liver function in older patients; dose adjustment should be considered in such patients.

Key Words:
  • Hepatocellular carcinoma
  • older age
  • unresectable tumor
  • relative dose intensity
  • molecular target agents
  • Received February 7, 2021.
  • Revision received February 23, 2021.
  • Accepted February 24, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (4)
Anticancer Research
Vol. 41, Issue 4
April 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib
RYU SASAKI, MASANORI FUKUSHIMA, MASAFUMI HARAGUCHI, SATOSHI MIUMA, HISAMITSU MIYAAKI, MASAAKI HIDAKA, SUSUMU EGUCHI, SATOSHI MATSUO, TOSHIHISA MATSUZAKI, SATSUKI HASHIMOTO, KAZUO OHBA, YUKI KUGIYAMA, HIROSHI YATSUHASHI, HIDETAKA SHIBATA, YASUHIDE MOTOYOSHI, MASAYA SHIGENO, SHINICHI IWATSU, YUJI KATO, NOBORU KINOSHITA, KAZUHIKO NAKAO
Anticancer Research Apr 2021, 41 (4) 2025-2032; DOI: 10.21873/anticanres.14970

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib
RYU SASAKI, MASANORI FUKUSHIMA, MASAFUMI HARAGUCHI, SATOSHI MIUMA, HISAMITSU MIYAAKI, MASAAKI HIDAKA, SUSUMU EGUCHI, SATOSHI MATSUO, TOSHIHISA MATSUZAKI, SATSUKI HASHIMOTO, KAZUO OHBA, YUKI KUGIYAMA, HIROSHI YATSUHASHI, HIDETAKA SHIBATA, YASUHIDE MOTOYOSHI, MASAYA SHIGENO, SHINICHI IWATSU, YUJI KATO, NOBORU KINOSHITA, KAZUHIKO NAKAO
Anticancer Research Apr 2021, 41 (4) 2025-2032; DOI: 10.21873/anticanres.14970
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Pelvic Recurrence After Curative Resection for Rectal Adenocarcinoma: Impact of Surgery on Survival
  • Glasgow Prognostic Score Predicts Survival and Recurrence Pattern in Patients With Hepatocellular Carcinoma After Hepatectomy
  • Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib
Show more Clinical Studies

Similar Articles

Keywords

  • Hepatocellular carcinoma
  • older age
  • unresectable tumor
  • relative dose intensity
  • molecular target agents
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire